Oncotarget

Corrections:

Correction: Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6

PDF  |  How to cite

Oncotarget. 2023; 14:83-84. https://doi.org/10.18632/oncotarget.28115

Metrics: PDF 587 views  |   ?  

Nicole Golob-Schwarzl1,2, Caroline Schweiger1, Carina Koller1, Stefanie Krassnig1, Margit Gogg-Kamerer1, Nadine Gantenbein1,2, Anna M. Toeglhofer1, Christina Wodlej1,2, Helmut Bergler3, Brigitte Pertschy3, Stefan Uranitsch4, Magdalena Holter5, Amin El-Heliebi6, Julia Fuchs6, Andreas Punschart7, Philipp Stiegler7, Marlen Keil8, Jens Hoffmann8, David Henderson9, Hans Lehrach10, Christoph Reinhard11, Christian Regenbrecht12, Rudolf Schicho13, Peter Fickert14, Sigurd Lax15 and Johannes Haybaeck1,2,16

1Institute of Pathology, Medical University of Graz, Graz, Austria
2Center for Biomarker Research in Medicine, Graz, Austria
3Institute of Molecular Biosciences, Karl-Franzens-University of Graz, Graz, Austria
4Department of Surgery, Hospital Brothers of Charity Graz, Graz, Austria 5
5Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
6Institute of Cell Biology, Histology and Embryology, Medical University Graz, Graz, Austria
7Department of Surgery, Medical University of Graz, Graz, Austria
8Experimental Pharmacology & Oncology Berlin GmbH-Berlin-Buch, Berlin, Germany
9Bayer AG, Berlin, Germany
10Max Planck Institute for Molecular Genetics, Berlin, Germany
11Eli Lilly & Company, Indianapolis, USA
12Cpo – cellular phenomics & oncology Berlin-Buch GmbH, Berlin, Germany
13Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
14Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria
15Department of Pathology, Hospital Graz South-West, Austria
16Department of Pathology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

Published: February 02, 2023

Copyright: © 2023 Golob-Schwarzl et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4A, the image of the immunoblot for row ‘elF1’ in the CC column is an accidental duplicate of the ‘elF3B’ image in the ‘RC’ column of Figure 3A. The corrected Figure 4, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:101224–101243. DOI: https://doi.org/10.18632/oncotarget.20642

Figure 4: eIF1, eIF5 and eIF6 expression levels in low and high grade CC and RC. (A) Western blot of eIF1, eIF5 and eIF6 from LG and HG CC and RC NNT. Equal amounts of protein from each pair were resolved on SDS PAGE and immunoblotted with antibodies directed against eIF1, eIF5, eIF6 and β-actin (loading control). (B) qRT-PCR of eIF1, eIF5 and eIF6 from LG and HG CC and RC compared to NNT. Three independent experiments were carried out. Bars represent mean ± SEM. ***p < 0.01, ***p < 0.001. Statistical analysis: 2-way ANOVA with Bonferroni posttest.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28115